Precision Wasn’t Just for Medicine: How AI Is Evolving Pharma Omnichannel Strategy

First, let’s simplify the hype 

When people say “AI” in a pharma commercial context, they’re usually mixing at least four or five very different capabilities: 

• Generative AI for content creation and adaptation 

• Predictive analytics for targeting and next-best-action 

• Machine learning models for propensity scoring and segmentation 

• Intelligent automation for orchestrating journeys across channels 

• Conversational AI for HCP and patient interaction 

Each of these has a different maturity curve, a different risk profile, and — critically — different regulatory and compliance needs. Treating them as one “AI strategy” is one of the most common mistakes I see. 

The strategist’s job is to sequence and prioritize these capabilities based on where your company actually is. And this is what Spectrum Science is good at. 

Intelligent Automation: How to Orchestrate in This  Omnichannel Reality 

Here’s a tension I encounter constantly in pharma commercial strategy: organizations have invested heavily in omnichannel capability — approved email, eDetailing, digital media, congress, patient support — and yet these channels still largely operate in silos, executing against their own metrics, with limited cross-channel intelligence. 

Intelligent automation is the solution to this. But not in the way most agencies pitch it. 

The pitch is usually: “Let the AI decide the next best action across all channels automatically.” Spectrum’s view: That’s the wrong ambition, at least right now, for most pharma organizations. 

The right ambition is human-in-the-loop orchestration where AI recommendations inform and accelerate human decision-making, never replacing it. Particularly in a regulated environment where a poorly timed, poorly contextualised communication to a prescriber or patient can have real consequences, both reputationally and from a compliance standpoint. 

What intelligent omnichannel automation actually looks like in practice: 

A brand team I consulted for had a genuine omnichannel infrastructure including field force, approved email, third-party digital media, a medical portal, and a patient support program. But the coordination between these was manual. A rep would visit an HCP, update the CRM, and that update would sit there until someone in the digital team happened to pull a report. 

We implemented an orchestration layer that automatically triggered contextual follow-up sequences based on field interactions. Rep visits a high-value cardiologist → system flags this in the automation platform → personalised email sequence initiates within 24 hours, serving educational content aligned to the specific conversation topics logged in the CRM → if email is opened and content is engaged with, the system flags the HCP for an MSL outreach recommendation → non-engagement triggers a different journey. 

Nothing in this workflow bypasses compliance review. All content variants are pre-approved. All journeys are mapped against medical-legal-regulatory (MLR) guardrails before deployment.  

The efficiency gains here compound over time. Once the system is trained and the journeys are approved, the marginal cost of personalizing at scale drops dramatically. You’re not personalizing one HCP at a time; you’re building intelligent decision trees that personalize systematically. How great is that?! 

How To Set-up for Successful Dynamic Personalization: The Hardest Thing to Do Well 

I want to be honest about this one, because the gap between the aspiration and the reality in pharma is wide. 

The aspiration: every HCP receives content that is perfectly tailored to their specialty, their patient population, their level of knowledge about your molecule, their preferred channel, and their position in the decision journey — served in real time, dynamically. 

The reality in most pharma organizations today: two or three segment variants of a core visual aid, slight message adaptations by specialty, and email subject line testing. 

That’s not nothing. But it’s not dynamic personalization. 

The reason the gap exists is not technology. The technology to do this exists and is increasingly accessible. The gap exists because of three structural challenges that are specific to pharma: 

1. Content supply chain bottlenecks. Dynamic personalization requires modular content at scale. Most pharma content is built as monolithic pieces — a single approved detail aid, a single approved email. The MLR process is built around reviewing these complete pieces, not a library of approved modules that can be assembled dynamically. Building a modular content architecture that can support genuine personalization requires a fundamental redesign of how content is created, tagged, and approved. This is organizational change, not just technology change.
2. Data fragmentation. To personalize intelligently, you need a unified view of the HCP — their engagement history, their prescribing behavior, their stated preferences, their channel affinity. Most pharma organizations have this data scattered across a CRM, a digital engagement platform, an approved email tool, and various third-party data providers that don’t talk to each other. AI can only personalize as well as the data it has access to. 
3. The compliance confidence gap. Even where the technology and data exist, I regularly encounter brand teams who are reluctant to push personalization further because they’re not confident about where the compliance guardrails are. This is often a perception problem as much as a real constraint. 

The path forward: Start with what I call structured personalization — a defined set of content variants, approved in advance, served based on clear segmentation rules. This is achievable now, within existing MLR processes, and produces measurable impact. As your content architecture matures and your data infrastructure improves, you can layer in progressively more dynamic approaches. 

Generative AI will eventually play a significant role here — particularly in adapting content for different channels, formats, and audiences from a single approved core message. But this requires a robust governance framework that most pharma organizations are still building. 

The Ethical and Compliance Dimension: Not a Footnote, But a Foundation 

There have been too many AI initiatives in pharma stumble not because the technology failed but because the ethical and compliance framework was bolted on as an afterthought. 

The guardrails that matter most: 

Transparency in algorithmic decision-making. Commercial teams need to be able to explain why a particular HCP is being targeted in a particular way. “The AI said so” is not an acceptable answer  for compliance, for field teams, or for the HCPs themselves if they ask. Build explainability into your models. 

Data governance and consent. The HCP data you’re feeding into predictive models needs to be handled with the same rigour you’d apply to any other commercial data. Know where it comes from, how it was collected, what consents govern its use, and how long you’re retaining it. 

Channel-specific compliance mapping. What’s permissible via a field force interaction may not be permissible via automated digital communication. Your orchestration logic needs to respect these channel-specific rules, not just apply a generic compliance layer. 

The companies getting this right are those that have involved medical, legal, regulatory, and privacy teams in the design of their AI frameworks, not just as reviewers of outputs after the fact. 

Where to Start Without Disrupting What’s Working 

For the strategist reading this who is under pressure to show AI-driven impact this year, not in three years, here is where I’d focus: 

1. Scoring on your existing CRM data. You almost certainly have more data than you’re using. Before investing in new data sources, explore what a propensity model built on your existing CRM and engagement data can tell you about which HCPs are most likely to engage, trial, or convert. This can often be implemented in weeks, not months, and produces immediate improvements in field force prioritization. 
2. Automated trigger-based follow-up. Map your highest-volume field interactions and identify the two or three follow-up actions that most consistently correlate with commercial outcomes. Automate those triggers. This doesn’t require a full omnichannel orchestration platform — many organizations can do this within their existing approved email infrastructure. 
3. Content performance analytics.If you’re not already systematically analyzing which content modules, messages, and formats drive the highest engagement and the strongest downstream commercial signals, start here. AI-powered content analytics tools can surface these patterns at a granularity that human analysis can’t match. The insights directly inform your next MLR submission and your next content development cycle. 
4. Segment-based personalization in digital channels. Take your existing HCP segments and build differentiated content journeys for each in your digital channels — different email cadences, different third-party media messages, different portal experiences. This is the minimum viable version of personalization and the foundation for everything more sophisticated that follows. 
5. Pilot a next-best-action recommendation tool for your field force. Several CRM platforms now have this capability built in or available as an add-on. Give your reps AI-generated recommendations for their next interaction like what to discuss, what material to leave, what follow-up to schedule. Measure the impact on call quality and downstream prescription behavior. This builds internal confidence in AI-assisted decision-making in a low-risk, high-visibility way. 

The pharma organizations that will win commercially over the next five years are not necessarily those with the biggest AI investment. They’re those with the clearest strategic intent about what they’re trying to achieve, the strongest data foundations to support intelligent decision-making, the organizational agility to act on AI-generated insights quickly, and the ethical discipline to deploy these capabilities responsibly.  

This is the conversation worth having. And now, more than ever, it’s worth acting on. Let the experts at Spectrum Science help. Reach out today and let’s start a conversation.